Search results for "risk factor"

showing 10 items of 4321 documents

Bioresorbable vascular scaffold versus everolimus-eluting stents or drug eluting balloon for the treatment of coronary in-stent restenosis: 1-Year fo…

2017

Objectives to compare the 1-year outcome between bioresorbable vascular scaffold (BVS), everolimus-eluting stent (EES), and drug-eluting balloon (DEB) for in-stent restenosis (ISR) treatment. Background BVS has been proposed as alternative for ISR treatment. To date a direct comparison between BVS and DES or DEB for ISR treatment is lacking. Methods We retrospectively analyzed all ISR lesions treated with BVS, DEB, and EES from January 2012 to December 2014. A total of 548 lesions (498 patients) were included. By applying two propensity-score matching, 93 lesions treated with BVS were compared with 93 lesions treated with DEB, and 100 lesions treated with BVS were compared to 100 lesions tr…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentUrology030204 cardiovascular system & hematologyProsthesis DesignBalloonRisk AssessmentCardiac CathetersCoronary Restenosis03 medical and health sciences0302 clinical medicineCoated Materials BiocompatibleRestenosisRisk FactorsAbsorbable ImplantsmedicineHumansRadiology Nuclear Medicine and imagingEverolimus030212 general & internal medicineAngioplasty Balloon CoronaryPropensity ScoreAgedRetrospective StudiesBioresorbable vascular scaffoldin stent restenosibusiness.industryIncidence (epidemiology)percutaneous coronary interventionStentPercutaneous coronary interventionCardiovascular AgentsDrug-Eluting StentsGeneral MedicineMiddle Agedmedicine.diseaseTreatment OutcomeItalyDrug-eluting stentPropensity score matchingFemalebioresorbable vascular scaffolddrug eluting balloonCardiology and Cardiovascular Medicinebusinessdrug eluting stent
researchProduct

Prognostic Value of Microvascular Obstruction and Infarct Size, as Measured by CMR in STEMI Patients

2014

The aim of this study was to evaluate the value of microvascular obstruction (MO) and infarct size as a percentage of left ventricular mass (15%LV), as measured by contrast-enhanced cardiac magnetic resonance, in predicting major cardiovascular adverse events (MACE) at 2 years in patients with ST-segment elevation myocardial infarction reperfused by primary percutaneous coronary intervention. Individual data from 1,025 patients were entered into the pooled analysis. MO was associated with the occurrence of MACE, defined as a composite of cardiac death, congestive heart failure, and myocardial re-infarction (adjusted hazard ratio: 3.74; 95% confidence interval: 2.21 to 6.34). IS% LV >= 25% w…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentmicrovascular obstructionHeart VentriclesMyocardial Infarction[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineRisk Assessmentcardiac magnetic resonance[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicinePercutaneous Coronary InterventionPredictive Value of TestsRecurrenceRisk FactorsInternal medicineCoronary CirculationMedicineinfarct sizeHumansRadiology Nuclear Medicine and imagingMyocardial infarctioncardiovascular diseasesAdverse effectComputingMilieux_MISCELLANEOUSAgedHeart Failurebusiness.industryMicrocirculationMyocardiumHazard ratioPercutaneous coronary interventionMiddle Agedmedicine.diseaseMagnetic Resonance ImagingConfidence intervalTreatment OutcomeRadiology Nuclear Medicine and imagingHeart failureNo reflow phenomenonCardiologyNo-Reflow PhenomenonFemaleprognosisCardiology and Cardiovascular MedicinebusinessMaceJACC. Cardiovascular imaging
researchProduct

Handgrip strength is not associated with risk of venous thromboembolism: a prospective cohort study.

2020

Objectives. Consistent evidence suggests an inverse and independent association between handgrip strength and arterial thrombotic disease. However, whether handgrip strength is related to future risk of venous thromboembolism (VTE) is uncertain. We sought to assess the prospective association between handgrip strength and VTE risk. Design. Handgrip strength was assessed using a hand dynamometer in a population-based sample of 864 men and women aged 61–74 years without a history of VTE at baseline in the Kuopio Ischemic Heart Disease prospective cohort study. Handgrip strength was allometrically scaled to account for the effect of body weight (handgrip strength/body weight2/3) and to normali…

Malemedicine.medical_specialtyTime Factorsvenous thromboembolism030204 cardiovascular system & hematologyHandgrip strengthRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinecohort studymedicineHumansThrombotic disease030212 general & internal medicineProspective StudiesProspective cohort studyFinlandAgedHand Strengthbusiness.industrymusculoskeletal neural and ocular physiologyAge FactorsVenous ThromboembolismMiddle AgedPrognosisbody regionscardiovascular systemFemaleCardiology and Cardiovascular Medicinebusinesshuman activitiesVenous thromboembolismcirculatory and respiratory physiologyCohort studyScandinavian cardiovascular journal : SCJ
researchProduct

Dietary fat intake and risk of cardiovascular disease and all-cause mortality in a population at high risk of cardiovascular disease.

2015

Background Dietary fat quality and fat replacement are more important for cardiovascular disease (CVD) prevention than is total dietary fat intake. Objective The aim was to evaluate the association between total fat intake and fat subtypes with the risk of CVD (myocardial infarction, stroke, or death from cardiovascular causes) and cardiovascular and all-cause death. We also examined the hypothetical effect of the isocaloric substitution of one macronutrient for another. Design We prospectively studied 7038 participants at high CVD risk from the PREvencion con DIeta MEDiterranea (PREDIMED) study. The trial was conducted from 2003 to 2010, but the present analysis was based on an expanded fo…

Malemedicine.medical_specialtyTrans fatMediterranean dietSaturated fatPopulationMedicine (miscellaneous)Lower riskDiet MediterraneanGastroenterologyCohort StudiesDietary Fats UnsaturatedRisk FactorsInternal medicineFood PreservedMedicineHumansMyocardial infarctionProspective StudiesMortalityeducationAgedProportional Hazards Modelschemistry.chemical_classificationAged 80 and overeducation.field_of_studyNutrition and Dieteticsbusiness.industryIncidencefood and beveragesTrans Fatty Acidsmedicine.diseaseDietary FatsEndocrinologychemistryCardiovascular DiseasesSpainElder Nutritional Physiological PhenomenaSaturated fatty acidFatty Acids UnsaturatedFast Foodslipids (amino acids peptides and proteins)FemalebusinessPolyunsaturated fatty acidFollow-Up StudiesThe American journal of clinical nutrition
researchProduct

Differential Prognostic Value of Galectin-3 According to Carbohydrate Antigen 125 Levels in Transcatheter Aortic Valve Implantation

2019

Galectin-3 (Gal-3) and carbohydrate antigen 125 (CA125) have been associated with adverse outcomes after transcatheter aortic valve implantation (TAVI). Experimental data have suggested a potential molecular interaction. Therefore, we assessed the association of Gal-3 and CA125 with prognosis after TAVI.A total of 439 patients were enrolled. The primary endpoint was a composite of all-cause mortality or readmission for worsening heart failure after TAVI.The primary endpoint occurred in 16.4%. Gal-3 was dichotomized at ≥ 8.71 ng/mL into elevated and not elevated. Gal-3 was elevated in 31.9% and was associated with a higher risk of the primary endpoint (25% vs 12.4%, HR, 2.26; P.001). After m…

Malemedicine.medical_specialtyTranscatheter aorticAdverse outcomesGalectin 3030204 cardiovascular system & hematologyRisk AssessmentTranscatheter Aortic Valve Replacement03 medical and health sciences0302 clinical medicineRisk FactorsCause of DeathGermanyInternal medicinemedicineClinical endpointHumansIn patientAgedRetrospective StudiesAged 80 and overbusiness.industryAortic Valve StenosisGeneral MedicinePrognosismedicine.diseaseSurvival RateGalectin-3CA-125 AntigenHeart failureAortic valve stenosisCardiologyFemalebusinessCarbohydrate antigenBiomarkersFollow-Up StudiesRevista Española de Cardiología (English Edition)
researchProduct

The assessment of surgical and non-surgical treatment of stage II medication-related osteonecrosis of the jaw

2017

Background Non-surgical treatment has generally been recommended for stage II medication-related osteonecrosis of the jaw (MRONJ) in preference to surgery. However, non-surgical treatment is not empirically effective. The aim of this study was to evaluate whether surgical or non-surgical treatment leads to better outcomes for stage II MRONJ. Material and Methods In this retrospective study, surgery was performed in a total of 28 patients while 24 patients underwent non-surgical treatment. The outcomes of both treatment approaches after 6 months were evaluated and statistically compared. In addition, risk factors for surgical and non-surgical treatments were assessed for each. Results Surgic…

Malemedicine.medical_specialtyTreatment outcomeMEDLINEDentistryStage ii03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineMedicineHumansGeneral DentistryAgedRetrospective StudiesAged 80 and overbusiness.industryResearchSignificant differenceOsteonecrosisNon surgical treatmentRetrospective cohort study030206 dentistryDrug holidaymedicine.disease:CIENCIAS MÉDICAS [UNESCO]Treatment OutcomeOtorhinolaryngology030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASSurgeryFemaleOral SurgerybusinessOsteonecrosis of the jawJaw DiseasesMedicina Oral, Patología Oral y Cirugía Bucal
researchProduct

Urinary neutrophil gelatinase-associated lipocalin and cystatin C compared to the estimated glomerular filtration rate to predict risk in patients wi…

2016

Abstract Introduction Impaired renal function, reflected by estimated glomerular filtration rate (eGFR) or cystatin C, is a strong risk predictor in the presence of acute myocardial infarction (AMI). Urinary neutrophil gelatinase-associated lipocalin (uNGAL) is an early marker of acute kidney injury. uNGAL might also be a good predictor of outcome in patients with cardiovascular disease. Aim of the present study was to evaluate the prognostic value of uNGAL compared to eGFR and cystatin C in patients with suspected AMI. Methods 1818 patients were enrolled with suspected AMI. Follow-up information on the combined endpoint of death or non-fatal myocardial infarction was obtained 6months after…

Malemedicine.medical_specialtyUrinary systemMyocardial InfarctionRenal function030204 cardiovascular system & hematologyurologic and male genital diseasesCohort Studies03 medical and health sciences0302 clinical medicineLipocalin-2Predictive Value of TestsRisk FactorsInternal medicinemedicineClinical endpointHumans030212 general & internal medicineMyocardial infarctionCystatin CAgedAged 80 and overFramingham Risk Scorebiologybusiness.industryAcute kidney injuryMiddle Agedmedicine.diseaseCystatin Cbiology.proteinCardiologyFemaleCystatinCardiology and Cardiovascular MedicinebusinessBiomarkersFollow-Up StudiesGlomerular Filtration RateInternational journal of cardiology
researchProduct

Testosterone Levels in Males with Type 2 Diabetes and Their Relationship with Cardiovascular Risk Factors and Cardiovascular Disease

2010

ABSTRACT Introduction One of the factors involved in type 2 diabetes in males is a reduction in levels of testosterone, which has been shown to predict resistance to insulin and the development of cardiovascular diseases. Aim To assess the levels of testosterone in patients with type 2 diabetes and to evaluate their relationship with cardiovascular risk factors, peripheral arterial disease (PAD) and silent myocardial ischemia (SMI). Methods Total testosterone and sex hormone binding globulin were measured and free and bioavailable testosterones were calculated using Vermeulen's formula. Levels of total testosterone ≥12 nmol/L or free testosterone >225 pmol/L were considered normal. PAD was …

Malemedicine.medical_specialtyUrologyEndocrinology Diabetes and MetabolismMyocardial IschemiaArterial Occlusive DiseasesType 2 diabetesEndocrinologySex hormone-binding globulinInsulin resistanceRisk FactorsDiabetes mellitusInternal medicineHumansMedicineTestosteroneAgedFramingham Risk Scorebiologymedicine.diagnostic_testbusiness.industryTestosterone (patch)Middle Agedmedicine.diseasePsychiatry and Mental healthEndocrinologyDiabetes Mellitus Type 2Reproductive MedicineCardiovascular Diseasesbiology.proteinInsulin ResistanceMetabolic syndromebusinessLipid profileThe Journal of Sexual Medicine
researchProduct

Definition of overactive bladder and epidemiology of urinary incontinence

1998

Abstract Objectives To review the definition of the overactive bladder and to summarize the results of epidemiologic studies on this specific disorder as well as urinary incontinence (UI) in general. Methods From a literature search covering the time period from 1954 through 1995, 48 epidemiologic studies and several other publications dealing with the prevalence and natural history of UI were reviewed. A metaanalysis of reported data was performed with respect to incontinence definitions, investigation methods, home country of survey, sex, and age groups. Results Differences in definitions of incontinence, target populations, and study design in different investigations resulted in inhomog…

Malemedicine.medical_specialtyUrologyMEDLINEUrinary incontinenceGlobal HealthAge DistributionQuality of lifeRisk FactorsTerminology as TopicEpidemiologyPrevalenceHumansMedicineSex DistributionUrinary Bladder NeurogenicGynecologybusiness.industryIncidenceIncidence (epidemiology)medicine.diseaseNatural historyUrinary IncontinenceOveractive bladderMeta-analysisFemalemedicine.symptombusinessClinical psychologyUrology
researchProduct

Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zole…

2008

Abstract Background In addition to other treatments, patients with prostate cancer (pCA) and bone metastasis receive bisphosphonates. Since 2003, a previously unknown side-effect of bisphosphonates—bisphosphonate-associated osteonecrosis of the jaws (BP-ONJ)—has been described, and frequency has since increased. An exact incidence is still unknown. Objectives The aim of this study was to assess the incidence and additional factors in the development of BP-ONJ. Design, setting, and participants From July 2006 to October 2007, patients with advanced pCA and osseous metastasis receiving bisphosphonate therapy in the Department of Urology or Haematology and Oncology at the Johannes-Gutenberg-Un…

Malemedicine.medical_specialtyUrologymedicine.medical_treatmentBone NeoplasmsZoledronic AcidProstate cancerRisk FactorsInternal medicineGermanymedicinePrevalenceHumansProspective cohort studyAgedRetrospective StudiesBisphosphonate-associated osteonecrosis of the jawBone Density Conservation AgentsDiphosphonatesbusiness.industryIncidence (epidemiology)ImidazolesOsteonecrosisBone metastasisProstatic NeoplasmsRetrospective cohort studyBisphosphonateMiddle Agedmedicine.diseasePrognosisSurgeryZoledronic acidCross-Sectional StudiesInjections IntravenousbusinessJaw Diseasesmedicine.drugFollow-Up StudiesEuropean urology
researchProduct